

DESCRIPTION


| | |
|---------------------------|---|
| Species Reactivity | Mouse |
| Specificity | Detects mouse DNAM-1/CD226 in ELISAs. In direct ELISAs, no cross-reactivity with recombinant human DNAM-1/CD226 is observed. |
| Source | Monoclonal Rat IgG _{2B} Clone # 838216 |
| Purification | Protein A or G purified from ascites |
| Immunogen | Mouse myeloma cell line NS0-derived recombinant mouse DNAM-1/CD226 Met1-Pro254 Accession # Q8K4F0 |
| Formulation | Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS. |

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

| | Recommended Concentration | Sample |
|-----------------------|--|---------------|
| Flow Cytometry | 2.5 µg/10 ⁶ cells | See Below |
| CyTOF-ready | Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation. | |

DATA



PREPARATION AND STORAGE

| | |
|--------------------------------|--|
| Reconstitution | Sterile PBS to a final concentration of 0.5 mg/mL. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 6 months, -20 to -70 °C under sterile conditions after reconstitution. |

BACKGROUND

DNAM-1 accessory molecule-1 (DNAM-1), also known as CD226, is a 65 kDa type I transmembrane glycoprotein that belongs to the immunoglobulin superfamily (1). Mature mouse DNAM-1 has a 236 amino acid (aa) extracellular domain (ECD) that contains two Ig-like C2-set domains, and possesses a 58 aa cytoplasmic region that contains motifs for binding PDZ domains and band 4.1 family proteins (1, 2). Within the ECD, mouse DNAM-1 shares 52% and 86% aa sequence identity with human and rat DNAM-1, respectively. Additional cDNA transcripts of mouse DNAM-1 may give rise to secreted or transmembrane isoforms with ECD deletions. DNAM-1 is expressed on several lymphoid and myeloid cell types and interacts with CD155/PVR and Nectin-2/CD112 (2-4). Ligation of DNAM-1 promotes the activation of NK cells, CD8⁺ T cells, and mast cells (3-7), induces dendritic cell maturation, initiates megakaryocyte and activated platelet adhesion to vascular endothelial cells, and stimulates monocyte extravasation; conversely, it inhibits the formation of osteoclasts (8-11). Platelet-endothelium interactions that are mediated by DNAM-1 enable the metastasis of tumor cells to the lung (12). On activated, but not resting NK, T, and mast cells, the *cis* association of DNAM-1 with CD18 contributes to tyrosine and serine phosphorylation of DNAM-1 during activation (7, 10, 13-15).

References:

1. Fuchs, A. and M. Colonna (2006) *Semin. Cancer Biol.* **16**:359.
2. Tahara-Hanaoka, S. *et al.* (2005) *Biochem. Biophys. Res. Commun.* **329**:996.
3. Bottino, C. *et al.* (2003) *J. Exp. Med.* **198**:557.
4. Tahara-Hanaoka, S. *et al.* (2004) *Int. Immunol.* **16**:533.
5. Shibuya, A. *et al.* (1996) *Immunity* **4**:573.
6. Dardalhon, V. *et al.* (2005) *J. Immunol.* **175**:1558.
7. Bachelet, I. *et al.* (2006) *J. Biol. Chem.* **281**:27190.
8. Reymond, N. *et al.* (2004) *J. Exp. Med.* **199**:1331.
9. Kakehi, S. *et al.* (2007) *Mol. Cell. Biochem.* **301**:209.
10. Kojima, H. *et al.* (2003) *J. Biol. Chem.* **278**:36748.
11. Tahara-Hanaoka, S. *et al.* (2006) *Blood* **107**:1491.
12. Morimoto, K. *et al.* (2007) *Oncogene* **27**:264.
13. Shibuya, K. *et al.* (1999) *Immunity* **11**:615.
14. Shibuya, K. *et al.* (2003) *J. Exp. Med.* **198**:1829.
15. Shibuya, A. *et al.* (1998) *J. Immunol.* **166**:1671.